AlphaFold predicted structure
HLA-DRB1 · P01911

Mean pLDDT
88.4/ 100
Confident
266 residues
Confidence breakdown
- Very high(≥ 90)71%
- Confident(70–90)13%
- Low(50–70)11%
- Very low(< 50)5%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
major histocompatibility complex, class II, DR beta 1
Annotations refreshed 10 hours ago.
Diagnostic Grade (Green)
COVID-19 research
UnknownCerebral vascular malformations
UnknownFamilial Meniere Disease
Gastrointestinal epithelial barrier disorders
Pneumothorax - familial
rheumatoid arthritis
multiple sclerosis
Pulmonary artery atresia
neurodegenerative disease
myeloid sarcoma
type 1 diabetes mellitus
systemic lupus erythematosus
systemic sclerosis
non-Hodgkin lymphoma
autoimmune hepatitis
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
HLA class II histocompatibility antigen, DRB1 beta chain
A beta chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the alpha chain HLA-DRA, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DRB1-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells (PubMed:15265931, PubMed:16148104, PubMed:22327072, PubMed:27591323, PubMed:29884618, PubMed:31495665, PubMed:8642306). Typically presents extracellular peptide antigens of 10 to 30 amino acids that arise from proteolysis of endocytosed antigens in lysosomes (PubMed:8145819). In the tumor microenvironment, presents antigenic peptides that are primarily generated in tumor-resident APCs likely via phagocytosis of apoptotic tumor cells or macropinocytosis of secreted tumor proteins (PubMed:31495665). Presents peptides derived from intracellular proteins that are trapped in autolysosomes after macroautophagy, a mechanism especially relevant for T cell selection in the thymus and central immune tolerance (PubMed:17182262, PubMed:23783831). The selection of the immunodominant epitopes follows two processing modes: 'bind first, cut/trim later' for pathogen-derived antigenic peptides and 'cut first, bind later' for autoantigens/self-peptides (PubMed:25413013). The anchor residue at position 1 of the peptide N-terminus, usually a large hydrophobic residue, is essential for high affinity interaction with MHCII molecules (PubMed:8145819)
HLA-DRB1 · P01911

Mean pLDDT
88.4/ 100
Confident
266 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0